April 11, 2024

$1,160M

$150M

–

–

$1.01B in option exercise fees, development, regulatory, and commercial milestones.

Undisclosed royalties

–

Phase II ARV-766, a PROTAC androgen receptor (AR) protein degrader for the treatment of prostate cancer. Additionally, Novartis will purchase the AR-V7 preclinical therapy and will be responsible for its development and commercial activities.

Development and Commercialization License

Collaborative Development, No Shared Cost

• Arvinas granted Novartis exclusive, worldwide rights to develop and commercialize ARV-766, a PROTAC androgen receptor (AR) protein degrader for treating prostate cancer.
• Novartis will also acquire the AR-V7 preclinical therapy and handle its development and commercialization.
• Arvinas will receive an upfront payment of $150 million.
• Arvinas is eligible for up to $1.01 billion in development, regulatory, and commercial milestones.
• Arvinas will also receive undisclosed tiered royalties for ARV-766.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.